Announcement Summary

Entity name

PROTEOMICS INTERNATIONAL LABORATORIES LTD

Announcement Type

New announcement

Date of this announcement

Friday October 23, 2020

The Proposed issue is:

Total number of +securities proposed to be issued for a placement or other type of issue

ASX +security code	+Security description	Maximum Number of +securities to be issued
PIQ	ORDINARY FULLY PAID	12.500.000

Proposed +issue date

Monday November 2, 2020

Refer to next page for full details of the announcement

Part 1 - Entity and announcement details

1.1 Name of +Entity

PROTEOMICS INTERNATIONAL LABORATORIES LTD

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

1.2 Registered Number Type

Registration Number

ACN

169979971

1.3 ASX issuer code

PIQ

1.4 The announcement is

1.5 Date of this announcement

Friday October 23, 2020

1.6 The Proposed issue is:

☑ A placement or other type of issue

Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 - Are any of the following approvals required for the placement or other type of issue?

- +Security holder approval
- Court approval
- Lodgement of court order with +ASIC
- ACCC approval
- FIRB approval
- Another approval/condition external to the entity

☑ No

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

Existing class

Will the proposed issue of this +security include an offer of attaching +securities? ⊗ No

Details of +securities proposed to be issued

ASX +security code and description

PIQ: ORDINARY FULLY PAID

Number of +securities proposed to be issued

12,500,000

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

Yes

In what currency is the cash consideration being paid?

What is the issue price per

+security?

AUD - Australian Dollar

AUD 0.48000

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

Part 7C -	Timetable
-----------	-----------

7C.1 Proposed +issue date

Monday November 2, 2020

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?
⊗ No

7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

✓ Yes

7D.1b (i) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?

12500000

7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?

⊗ No

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?

☑ No

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?
⊗ No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?

⊗ No

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue?

⊗ Yes

7E.1a Who is the lead manager/broker?

Euroz Hartleys Securities Limited (AFSL 243302)

Proposed issue of securities

7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

Management fee of 2% of the total amount raised under the Placement Equity raising fee of 4% of the total amount raised under the Placement

1,100,000 options with exercise price of \$0.75 per option and expiring 2 years after the date of issue, in consideration for advisory services to be provided by Euroz Hartleys Securities Limited for a six month period following completion of the Placement

7E.2 Is the proposed issue to be underwritten? ⊗ No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

1,100,000 options with exercise price of \$0.75 per option and expiring 2 years after the date of issue, in consideration for services provided by Candour Advisory Pty Ltd as Corporate Advisor to the Placement

Part 7F - Further Information

7F.01 The purpose(s) for which the entity is issuing the securities

Manufacture & up-scaling of reagent inventory for the PromarkerD diagnostic test
Marketing of, & accelerating regulatory approvals for PromarkerD
Accelerating the development of the Promarker pipeline
General working capital

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds? ⊗ No

7F.2 Any other information the entity wishes to provide about the proposed issue